Literature DB >> 12429287

Hormonal therapy for prostate cancer: primum non nocere.

Aaron J Milbank, Robert Dreicer, Eric A Klein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429287     DOI: 10.1016/s0090-4295(02)01867-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  4 in total

1.  Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Authors:  J Paul Monk; Susan Halabi; Joel Picus; Arif Hussain; George Philips; Ellen Kaplan; Tim Ahles; Lin Gu; Nicholas Vogelzang; William K Kelly; Eric J Small
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

2.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  Arch Intern Med       Date:  2006-02-27

3.  Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells.

Authors:  Hosea F Huang; Thomas F Murphy; Ping Shu; Arnold B Barton; Beverly E Barton
Journal:  Mol Cancer       Date:  2005-01-12       Impact factor: 27.401

4.  Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea.

Authors:  Do Kyung Kim; Hye Sun Lee; Ju-Young Park; Jong Won Kim; Hyun Kyu Ahn; Jee Soo Ha; Kang Su Cho
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.